These press releases are for business and financial media.
-
- 28 May 1999
- CLOSE OF ASTRAZENECA MERGER OFFERS - ACCEPTANCES RECEIVED FROM SHAREHOLDERS REPRESENTING OVER 99.6 PER CENT OF THE SHARES IN ASTRA AstraZeneca announces that by 21st May 1999, the closing date of the Merger Offers, it has received acceptances from Astra shareholders representing in total 99.6 per cent of Astra's shares and 99.7 per cent of the voting rights attaching to Astra's shares.
-
- 21 May 1999
- ASTRAZENECA 1999 AGM TRADING STATEMENT AstraZeneca: off to a firm start
-
- 19 May 1999
- SPEECH BY TOM MCKILLOP AT ASTRAZENECA INFORMATION MEETING IN STOCKHOLM Over 6,400 shareholders attended the information meeting arranged by AstraZeneca in the sports arena Globen in Stockholm on 19 May. Below you find the speech by Tom McKillop, Chief Executive of AstraZeneca, at the meeting. Attached are also his overhead slides (Acrobat file, 24 kb).
-
- 12 May 1999
- ASTRAZENECA INTENDS TO APPEAL FOLLOWING REVIEW OF PATENT RULING IN AUSTRALIA AstraZeneca intends to appeal a patent ruling pertaining to omeprazole (Losec®) handed down today by The Federal Court of Australia in Sydney in a dispute with the generic company Alphapharm Pty Ltd. The court clearly established, that under Australian patent law, the formulation used by Alphapharm in its generic omeprazole version infringed AstraZeneca's patented formulation technology. However, the court declared, that under Australian patent law, AstraZeneca's formulation patent was invalid.
-
- 12 May 1999
- ASTRAZENECA SELLS SPECIALTY CHEMICALS BUSINESS AstraZeneca today announced it has agreed to sell Zeneca Specialties for a cash amount of $2.1 billion (£1.3 bn) in a buyout jointly financed by Cinven and Investcorp.
-
- 05 May 1999
- ASTRA FILES SUIT AGAINST GERMAN GENERIC COMPANY Astra has filed suit in Germany against the German generic company Azupharma. The company recently launched a generic capsule version of omeprazole in Germany. Omeprazole is the substance used in Losec®.
-
- 30 April 1999
- MERGER OFFERS ACCEPTANCES - OVER 99 PER CENT AstraZeneca announces that it has now received in total acceptances of the Merger Offers from Astra shareholders representing 99.4 per cent of Astra's shares and 99.5 per cent of the voting rights attaching to Astra's shares.
-
- 22 April 1999
- SALES OF PRILOSEC® (LOSEC®) IN THE U.S. UP 23 PERCENT DURING FIRST QUARTER OF 1999 Total sales of Prilosec (Losec) in the U.S. during the period January - March 1999 amounted to USD 895 m. (1998: 730 m.), an increase of 23 percent. Growth in total prescriptions February year-to-date was approximately 20 percent.
-
- 21 April 1999
- CHAIRMAN OF ASTRAZENECA HAS BOUGHT ASTRAZENECA-SHARES On 20 April 1999, Dr Percy Barnevik, Chairman of AstraZeneca, bought 100.000 AstraZeneca-shares at a price of SEK 342.50 per share.
-
- 19 April 1999
- COMPULSORY ACQUISITION OF ASTRA AB SHARES AstraZeneca PLC announces that the compulsory acquisition procedure has been initiated through its wholly owned subsidiary Zeneca Holding AB to acquire for cash those Astra shares, including shares underlying Astra ADSs, not tendered under the Merger Offers. Zeneca Holding AB owns, including subsidiary holdings, 96.2 percent of the total Astra shares representing 96.4 percent of the total voting rights attaching to Astra shares.
-
- 12 April 1999
- DELISTING OF ASTRA AB AstraZeneca PLC announces that Astra AB intends to apply for delisting of Astra A and B shares on the Stockholm and London Stock Exchanges with effect from Monday 26 April 1999. The last day for trading in the Astra shares on the Stockholm and London Stock Exchanges is expected to be Friday 23 April, 1999. Trading in the Astra A ADSs on the New York Stock Exchange is expected to be suspended from and including 23 April 1999, with such ADSs being delisted approximately 20 days thereafter. Trading in the
-
- 06 April 1999
- MERGER OFFERS DECLARED UNCONDITIONAL Astra and Zeneca announce that all the conditions to the Merger Offers made by Zeneca for the issued share capital of Astra have been satisfied and that the Merger Offers are unconditional. The Merger has now been completed.
-
- 25 March 1999
- ASTRAZENECA MERGER - CLOSING TIMETABLE AND REVISED DIVIDEND PAYMENT DATES Astra AB and Zeneca Group PLC announce that, as a result of the US anti-trust approval announced earlier today, they are able to provide further details of certain aspects of the closing timetable of the proposed merger. US anti-trust approval fulfils the only remaining regulatory consent required to effect the proposed merger.
-
- 25 March 1999
- FTC APPROVE ASTRAZENECA MERGER Zeneca Group PLC and Astra AB announce that very significant progress has been made with regard to the US competition approval process, which is the only remaining regulatory consent required to effect the proposed Merger between the two companies. In particular, agreement has now been reached with the Staff of the Bureau of Competition of the Federal Trade Commission (FTC) on the terms of a Consent Decree which relates to a narrow product area. The Consent Decree and related agreements are subject to the
-
- 18 March 1999
- ZENECA GROUP PLC/ASTRA AB MERGER AGREEMENT REACHED WITH FTC STAFF AND INITIAL OFFER PERIOD EXTENDED Not for Release, Publication or Distribution, in whole or in part, in or into Canada, Australia or Japan Zeneca Group PLC and Astra AB announce that very significant progress has been made with regard to the US competition approval process, which is the only remaining regulatory consent required to effect the proposed Merger between the two companies. In particular, agreement has now been reached with the Staff of the Bureau of Competition of the Federal Trade Commission (FTC) on the terms of a Consent
-
- 01 March 1999
- EU APPROVES OF ASTRAZENECA MERGER Zeneca Group PLC and Astra AB today announce that the Commission of the European Union has approved the proposed merger of Astra and Zeneca Group PLC.
-
- 18 February 1999
- ZENECA GROUP PLC: RESULT OF VOTES AT EXTRAORDINARY GENERAL MEETING Zeneca Group PLC announces that its shareholders have today approved all of the ordinary and special resolutions set out in the notice of the EGM contained in the Zeneca Circular dated 21st January 1999.
-
- 12 February 1999
- ASTRAZENECA MERGER - COMPETITION AUTHORITY APPROVAL PROGRESS Astra AB announce that Astra and Zeneca confirm that the period for the European Commission's Phase I review of the proposed merger has been extended to 1st March 1999. This is to enable the parties and the Commission to discuss certain minor aspects of the merger further.
-
- 21 January 1999
- FURTHER INFORMATION REGARDING THE MERGER BETWEEN ASTRA AND ZENECA The stock exchanges in Stockholm, London and New York have now approved the documentation regarding the merger between Astra and the British bioscience company Zeneca. The international prospectus will be made available at Astra AB, PR & Information, Södertälje, and at Enskilda Securities, Nybrokajen 5, Stockholm. In this connection, Astra will start distributing the prospectus.
-
- 21 January 1999
- ZENECA ANNOUNCES PUBLICATION OF ASTRAZENECA MERGER DOCUMENTATION, YEAR END TRADING UPDATE AND NINE MONTHS INTERIM RESULTS Not for Release, Publication or Distribution, in whole or in part, in or into Canada, Australia or JapanThe Board of Zeneca Group PLC announces that the formal merger documents in connection with its proposed merger of equals with Astra AB to form AstraZeneca will be published today.
-
- 18 January 1999
- COMPETITION AUTHORITIES RECEIVE ASTRAZENECA MERGER FILINGS Filings for competition law approval of the AstraZeneca merger have been made to the European Commission and the Federal Trade Commission in the U.S., it was announced today. Both regulatory bodies received the filing last Friday (January 15). They will consider the proposed merger of equals between Zeneca, a UK-based company, and Astra, of Sweden, announced last month.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
